Holen Sie sich die Stockscreener-App
1.81
2.84%
0.05
Schlusskurs vom Vortag:
$1.76
Offen:
$1.73
24-Stunden-Volumen:
210.18K
Relative Volume:
1.27
Marktkapitalisierung:
$12.05M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-18.68M
KGV:
-0.2448
EPS:
-7.3948
Netto-Cashflow:
$-15.70M
1W Leistung:
+25.69%
1M Leistung:
+120.19%
6M Leistung:
-75.91%
1J Leistung:
-84.76%
1-Tages-Spanne:
$1.71
$1.90
1-Wochen-Bereich:
$1.401
$2.1999
52-Wochen-Spanne:
$0.6201
$12.40
Fibrobiologics Inc Stock (FBLG) Company Profile
Firmenname
Fibrobiologics Inc
Sektor
Branche
Telefon
281-671-5150
Adresse
455 E. MEDICAL CENTER BLVD, HOUSTON
Compare FBLG vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
1.81 | 8.59M | 0 | -18.68M | -15.70M | -7.3948 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-12 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-24 | Eingeleitet | Maxim Group | Buy |
Fibrobiologics Inc Aktie (FBLG) Neueste Nachrichten
FibroBiologics receives Australian patent for disc disease therapy - Investing.com
FibroBiologics receives Australian patent for disc disease therapy By Investing.com - Investing.com Canada
FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease - Morningstar
Hundreds of millions face disc disease; FibroBiologics' patent pairs cannabidiol and cell therapy - Stock Titan
FibroBiologics Says Preclinical Data Shapes Design of Further Studies for Degenerative Joint Treatment - Sahm
FibroBiologics reports cartilage repair in animal study By Investing.com - Investing.com South Africa
FibroBiologics reports cartilage repair in animal study - Investing.com
Animal joints showed cartilage repair within four weeks of one injection - Stock Titan
BRIEF-Fibrobiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair In Preclinical Study Of Degenerative Joints - Bitget
Armistice Capital discloses 9.99% FibroBiologics (FBLG) stake via Master Fund - Stock Titan
FibroBiologics Inc - Smartkarma
FBLG Q2 2026 Earnings: Narrower Loss Beats Estimates as Pre-Revenue Biotech Advances Fibroblast Pipeline - vinanet.vn
FBLG Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 7.77% Share GainEarnings Surprise Stocks - vinanet.vn
FibroBiologics receives patent for islet transplant method By Investing.com - Investing.com UK
FibroBiologics receives patent for islet transplant method - Investing.com
Fibrobiologics Granted US Patent Covering The Use Of Fibroblasts - TradingView
FibroBiologics Patent Could Help Stretch Scarce Donor Pancreases - Stock Titan
FibroBiologics (FBLG) Holds at $0.98 as Biotech Stock Tests Key Trading RangeFibonacci Extension - vinanet.vn
Fibrobiologics Inc (FBLG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
FBLG Q2 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesRevenue Report - vinanet.vn
Fibrobiologics Inc (FBLG) Stock News Today - TradingKey
FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage - marketscreener.com
FibroBiologics patent covers Sox9 turning fibroblasts into cartilage cells - Stock Titan
H.C. Wainwright cuts FibroBiologics price target to $6 on model adjustments - Investing.com
FibroBiologics Faces Material Clinical Trial and Regulatory Risks That Threaten Commercialization Timeline and Long-Term Outlook - TipRanks
FibroBiologics, Inc. Revenue Breakdown – NASDAQ:FBLG - TradingView
FBLG: Advanced clinical pipeline, reduced R&D costs, raised $12M, and expanded patent assets - tradingview.com
FibroBiologics Q2 EPS beats estimates as losses narrow 72.5% - scanx.trade
FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate - PR Newswire
FIBROBIOLOGICS ($FBLG) Releases Q2 2026 Earnings - Quiver Quantitative
FibroBiologics, Inc. 2Q 2026: Net loss $(4.12M), EPS $(0.66) — 10-Q Summary - TradingView
FibroBiologics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Form DEF 14A FIBROBIOLOGICS For: 31 July By Investing.com - Investing.com Nigeria
FBLG Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Stage ContinuesEarnings Decline Risk - Vinanet
FBLG Q1 2026 Earnings: EPS Misses Slightly as Pre‑Revenue Biotech Continues R&D FocusForward EPS Estimate - vinanet.vn
Fibrobiologics Inc (FBLG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Fibrobiologics Inc (FBLG) Earnings Date & Reports & Earnings News - TradingKey
Fibrobiologics Inc (FBLG) Valuation: PE, PB & Fair Value Analysis - TradingKey
FBLG|Fibrobiologics Inc|Price:0.681|Chg%:-0.031 - TradingKey
Fibrobiologics Inc (FBLG) Institutional Confidence - TradingKey
Fibrobiologics Inc (FBLG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Fibrobiologics Inc expected to post a loss of 72 cents a shareEarnings Preview - TradingView
Fibrobiologics Inc (FBLG) Balance Sheet - TradingKey
FBLG|Fibrobiologics Inc|Price:0.712|Chg%:-0.024 - TradingKey
FibroBiologics Market Sentiment - Benzinga España
Fibrobiologics Inc (FBLG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fibrobiologics Inc (FBLG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
FBLG Q1 2026 Earnings: Narrow EPS Miss Against Estimates Amid Pre-Revenue Development Stage - vinanet.vn
FBLG|Fibrobiologics Inc|Price:1.020|Chg%:+0.152 - TradingKey
TradingKey - TradingKey
FibroBiologics Faces Nasdaq Delisting, Appeals Planned - TipRanks
Finanzdaten der Fibrobiologics Inc-Aktie (FBLG)
Umsatz
Nettogewinn
Free Cashflow
ENV
Fibrobiologics Inc-Aktie (FBLG) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER |
Mar 03 '26 |
Buy |
0.41 |
18,200 |
7,373 |
5,942,275 |
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER |
Mar 02 '26 |
Buy |
0.35 |
17,428 |
6,152 |
5,924,075 |
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER |
Mar 04 '26 |
Buy |
0.38 |
15,872 |
6,006 |
5,958,147 |
| Davis Jason | Chief Financial Officer |
Mar 02 '26 |
Buy |
0.41 |
70,000 |
28,973 |
70,000 |
| GARCIA RUBEN A | General Counsel |
Feb 27 '26 |
Buy |
0.33 |
40,000 |
13,056 |
180,000 |
| GARCIA RUBEN A | General Counsel |
Dec 11 '25 |
Buy |
0.34 |
140,000 |
47,600 |
140,000 |
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):